ICU Medical (ICUI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Mar, 2026Executive summary
The annual meeting will be held virtually on May 13, 2026, with seven directors up for election and several key proposals on the agenda.
Shareholders will vote on director elections, auditor ratification, executive compensation, amendments to governance documents, and shareholder rights.
The board recommends voting for all management proposals except a shareholder proposal to lower the special meeting threshold to 10%.
The company emphasizes pay-for-performance in executive compensation and strong governance practices.
Sustainability, diversity, and community engagement are highlighted as ongoing priorities.
Voting matters and shareholder proposals
Proposals include electing seven directors, ratifying Deloitte & Touche LLP as auditor, approving executive compensation, adopting simple majority voting, and establishing a 25% threshold for shareholders to call special meetings.
Proposal 6 allows adjournment to solicit more proxies if needed for Proposal 5.
Proposal 7, a shareholder proposal for a 10% special meeting threshold, is opposed by the board.
Board recommends FOR all management proposals and AGAINST the shareholder proposal.
Board of directors and corporate governance
The board consists of seven directors, six of whom are independent.
Board committees include Audit, Compensation, and Nominating, all composed of independent directors.
Lead Independent Director role established to enhance governance.
Board tenure averages 8.4 years, with a mix of experience and new perspectives.
Directors are elected annually, and a director retirement policy is in place.
Latest events from ICU Medical
- Margin expansion, pump upgrades, and software innovation drive growth amid integration progress.ICUI
2026 KeyBanc Capital Markets Healthcare Forum18 Mar 2026 - Innovation, unified platforms, and margin expansion drive growth and future capital returns.ICUI
47th Annual Raymond James Institutional Investor Conference9 Mar 2026 - 2026 guidance targets $400–$430M adjusted EBITDA and low- to mid-single-digit organic growth.ICUI
Q4 202519 Feb 2026 - Q2 revenue up 8.6%, net loss widens, but full-year earnings guidance is raised.ICUI
Q2 20242 Feb 2026 - Stabilized operations and innovation position the company for growth and margin expansion.ICUI
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Innovation, margin gains, and integration fuel growth and future opportunities in IV therapy.ICUI
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Q3 revenue up 6.5% YoY; IV solutions JV with Otsuka to drive growth and reduce debt.ICUI
Q3 202414 Jan 2026 - Joint venture and innovation drive growth, margin expansion, and operational stability.ICUI
UBS Global Healthcare Conference 202414 Jan 2026 - Operational improvements, innovation, and a strategic JV drive growth and margin expansion.ICUI
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026